Teva Pharmaceutical Industries, Ltd.: Disorders of Excessive Somnolence trials
The registry lists 13 Disorders of Excessive Somnolence studies with Teva Pharmaceutical Industries, Ltd. as lead sponsor. 0 are open to participants now and 11 have results posted.
Phase 3 10Phase 4 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work DisorderCompletedNCT01080807Phase 4Results posted
- Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag DisorderCompletedNCT00758498Phase 3Results posted
- Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory PerformanceCompletedNCT00711516Phase 4Results posted
- Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and DepressionCompletedNCT00518986Phase 4Results posted
- Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00228566Phase 3Results posted
- Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive SleepinessCompletedNCT00228553Phase 3Results posted
- Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSDCompletedNCT00080288Phase 3Results posted
- Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) SyndromeCompletedNCT00079677Phase 3Results posted
- Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With NarcolepsyCompletedNCT00078377Phase 3Results posted
- Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)CompletedNCT00078325Phase 3Results posted
- Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep DisorderCompletedNCT00078312Phase 3Results posted
- Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00107809Phase 3
- Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With NarcolepsyCompletedNCT00107796Phase 3